Analysis reveals ERG regulates TGF-β signaling, impacting cell migration and invasion in cervical cancer.
In healthy cells, TGF-β signaling is crucial to the cell cycle. The pathway promotes apoptosis, suppresses cellular proliferation, and stimulates immune cell activation. In malignant cells, however, TGF-β signaling has been shown to drive the proliferation of cancer through migration and metastasis, immune evasion, and angiogenesis. The effects of TGF-β signaling shift from tumor-suppressing to tumor-promoting as cancer progresses. Using TCGA data, we identified genes coexpressed with TβRIII. After determining which genes had the highest correlation, we used Enrichr to conduct pathway analysis. Pathway analysis indicated a relationship with ERG, leading us to hypothesize that ERG regulates TβRIII and other related genes. ERG seems to share many cancer behaviors with TGF-β, such as proliferation, invasion, and overall cell survival in cervical cancer. Kaplan-Meier Survival plots of TCGA data support decreased survival rates with high ERG expression in several other cancers as well, for the scope of this study, cervical cancer specifically. However, ERG has not been extensively investigated in this context. Western Blot analysis confirmed the presence of ERG expression in HeLa cells. Functional assays demonstrated that manipulating HeLa cells to express a knockdown of ERG led to a significant decrease in cell migration. The addition of TGF-β to HeLa cells with ERG knockdown (shERG) partially restores migration, suggesting that TGF-β could potentially compensate for the loss of ERG expression. To further investigate the effects of ERG on TGF-β, galunisertib, a known inhibitor of TGF-β signaling, was used. Analysis of scratch assays showed that in control HeLa cells, migration rates significantly reduced when exposed to galunisertib. In HeLa-shERG cells, migration was reduced as well; however, galunisertib failed to have the same decreased migration pattern in HeLa-shERG cells, suggesting that ERG and TGF-β pathways may converge in some way. HeLa-shERG significantly reduced the expression of TGFβ-I as well as decreasing the activation of SMAD2, a transcription factor that plays a significant role in TGF-β signaling. Invasion assays exposed HeLa cells’ ability to travel throughout the extracellular matrix when manipulating TGF-β and ERG to measure metastasis. ChIP-seq is being done to investigate the possible interactions between TGFB signaling and ERG occupancy on the genome in cervical cancer, which will be compared to ERG sites in extensively studied cancers. Together, these findings suggest that ERG promotes cervical cancer cell migration and invasion, at least in part by regulating TGF-β signaling. Citation Format: Kaitlyn Marie Eidson, Hannah Mckinsey Fitzgibbons, Logan J. Baker, Benjamin M. Greulich, . Investigating the interplay of transcription factor, ERG, and TGF-beta signaling in cervical cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7355.
No takes yet. Share an insight, caveat, or question.
Eidson et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: